Eurofins-Cerep SA
PAR:ALECR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Textron Inc
NYSE:TXT
|
US |
Eurofins-Cerep SA
Retained Earnings
Eurofins-Cerep SA
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurofins-Cerep SA
PAR:ALECR
|
Retained Earnings
€60.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Retained Earnings
€4.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
21%
|
|
Eurofins-Cerep SA
Glance View
Eurofins-Cerep SA engages in providing preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 211 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. In December 2013, it sold Cerep Inc, its American subsidiary, to Eurofins-Panlabs Inc, part of the Eurofins Scientific SE group.
See Also
What is Eurofins-Cerep SA's Retained Earnings?
Retained Earnings
60.8m
EUR
Based on the financial report for Dec 31, 2024, Eurofins-Cerep SA's Retained Earnings amounts to 60.8m EUR.
What is Eurofins-Cerep SA's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
27%
Over the last year, the Retained Earnings growth was 13%. The average annual Retained Earnings growth rates for Eurofins-Cerep SA have been 21% over the past three years , 27% over the past five years .
